𝔖 Bobbio Scriptorium

✦ LIBER ✦

Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: Results from controlled clinical trials

Book ID: 116583934
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 51 KB
Volume: 58
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2007.10.534

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tasocitinib (CP-690,550), an oral Janus

Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, consistently improves the clinical signs of moderate to severe psoriasis in different body regions

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Impact of adalimumab treatment on patien

Impact of adalimumab treatment on patient‐reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

✍ Revicki, Dennis A.; Willian, Mary Kaye; Menter, Alan; Gordon, Kenneth B.; Kimbal 📂 Article 📅 2007 🏛 Informa plc 🌐 English ⚖ 236 KB

Comparative efficacy of biological treat

Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response

✍ Signorovitch, J.E.; Betts, K.A.; Yan, Y.S.; LeReun, C.; Sundaram, M.; Wu, E.Q.; 📂 Article 📅 2015 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Secukinumab efficacy and safety in subje

Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: Results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE)

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Apremilast, an oral phosphodiesterase 4

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1)

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Efficacy of efalizumab for the treatment

Efficacy of efalizumab for the treatment of moderate to severe plaque psoriasis: A prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 51 KB